Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting CD44
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intraperitoneal, Intratumoral, Intradermal, Inhalation, Parenteral, Implant
01
Overview
siRNA targeting CD44 is a target-specific RNA interference (RNAi) modality designed to silence the expression of CD44, a cell-surface glycoprotein overexpressed in various cancers and cancer stem cells. CD44 plays a critical role in cell adhesion, migration, proliferation, and epithelial-to-mesenchymal transition (EMT), and is associated with therapeutic resistance and metastasis. By delivering small interfering RNA (siRNA) sequences complementary to CD44 mRNA, this approach triggers the RNA-induced silencing complex (RISC) to degrade CD44 transcripts, thereby downregulating CD44 protein expression. While widely utilized as a research reagent to study CD44 biology and overcome drug resistance in preclinical models, various delivery systems, such as nanoparticles, exosomes, and peptide carriers, are being investigated to translate CD44-targeted siRNA therapies into clinical applications.
- Other names
- anti-CD44 siRNAanti-CD-44 siRNAanti-CD 44 siRNACD44 siRNACD-44 siRNACD 44 siRNAsiCD44siCD-44siCD 44small interfering RNA targeting CD44
02
Targets
CD44 (CD44 antigen)AGO2 (Argonaute RISC catalytic component 2)
Beyond the preview
Go deeper on siRNA targeting CD44.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA targeting CD44.